Barclays analyst Stephanie Davis expects Walgreens Boots Alliance’s (WBA) liquidity concerns to persist after the company sold $160M of BrightSpring Health (BTSG) shares to KKR and paid $107M to resolve alleged False Claims Act violations. The cash inflow “represents a helpful offset” to Justice Department news, the analyst tells investors in a research note. The firm still believes liquidity concerns around Walgreens are likely to persist, supporting its Underweight rating and $7 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WBA:
- KKR to purchase 11.62M shares of BrightSpring Health from Walgreens
- Walgreens pays $106.8M to resolve False Claims Act allegations
- Walgreens Boots Alliance price target lowered to $16 from $22 at TD Cowen
- Walgreens Stock (WBA) Plummets to a Multi-Decade Low, Leaving Investors Wondering
- Walgreens Boots Alliance price target lowered to $7.50 from $11 at BofA